Literature DB >> 24378425

Optical coherence tomography predicts visual outcome in acute central retinal vein occlusion.

Jaesang Ko1, Oh W Kwon, Suk H Byeon.   

Abstract

PURPOSE: To investigate the clinical features of central retinal vein occlusion (CRVO) in relation to the presence of a prominent middle limiting membrane (p-MLM) sign on presenting optical coherence tomography, which may suggest macular ischemia and poor visual outcome.
METHODS: Fifty consecutive eyes with acute CRVO of <1 month of symptom duration before presentation were retrospectively reviewed. A hyperreflective line located in the outer plexiform layer (p-MLM) in optical coherence tomography was used as a sign of acute ischemia. Cases with p-MLM were grouped and compared with the group of eyes with no p-MLM sign (non-MLM group) for clinical features including visual acuities, central fovea thickness, and CRVO types.
RESULTS: Among the 50 eyes, 14 (28%) eyes showed a p-MLM sign, 21 (42%) eyes did not, and others had equivocal findings. Eyes with p-MLM sign presented worse initial and final best-corrected visual acuity compared with the non-MLM group (1.10 ± 0.72 vs. 0.47 ± 0.49 logMAR in the initial best-corrected visual acuity, P = 0.007; and 1.08 ± 0.86 vs. 0.32 ± 0.41 logMAR in the final best-corrected visual acuity, P = 0.044) in patients with a follow-up duration of 6 months or longer. The p-MLM group eyes showed a higher tendency toward being classified as ischemic type CRVO (57.1 vs. 4.8%, P = 0.001).
CONCLUSION: Central retinal vein occlusion showing p-MLM on optical coherence tomography had worse visual outcome with higher incidence of being classified into ischemic type CRVO.

Entities:  

Mesh:

Year:  2014        PMID: 24378425     DOI: 10.1097/IAE.0000000000000054

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

Review 1.  [Biomarkers in the treatment of retinal vein occlusion].

Authors:  Jakob Siedlecki; Lars-Olof Hattenbach; Nikolas Feltgen; Siegfried G Priglinger
Journal:  Ophthalmologie       Date:  2022-10-06

2.  Hyperreflectivity of Inner Retinal Layers as a Quantitative Parameter of Ischemic Damage in Acute Retinal Vein Occlusion (RVO): An Optical Coherence Tomography Study.

Authors:  Olga Furashova; Egbert Matthè
Journal:  Clin Ophthalmol       Date:  2020-08-24

3.  Multimodal imaging in acute retinal ischemia: spectral domain OCT, OCT-angiography and fundus autofluorescence.

Authors:  Nikolaus Feucht; Daniel Zapp; Lukas Reznicek; Chris P Lohmann; Mathias Maier; Christian S Mayer
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.779

4.  Association of Disorganization of Retinal Inner Layers with Ischemic Index and Visual Acuity in Central Retinal Vein Occlusion.

Authors:  Duncan Berry; Akshay S Thomas; Sharon Fekrat; Dilraj S Grewal
Journal:  Ophthalmol Retina       Date:  2018-06-08

5.  Assessment of ischemia in acute central retinal vein occlusion from inner retinal reflectivity on spectral domain optical coherence tomography.

Authors:  David J Browning; Omar S Punjabi; Chong Lee
Journal:  Clin Ophthalmol       Date:  2016-12-22

6.  The Retrobulbar Spot Sign and Prominent Middle Limiting Membrane as Prognostic Markers in Non-Arteritic Retinal Artery Occlusion.

Authors:  Marlena Schnieder; Charlotte V Fischer-Wedi; Sebastian Bemme; Mai-Linh Kortleben; Nicolas Feltgen; Jan Liman
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

7.  Semi-automated quantitative analysis of the middle limiting membrane in tubercular serpiginous-like choroiditis using swept-source optical coherence tomography.

Authors:  Aniruddha Agarwal; Gagan Kalra; Rupesh Agrawal; Reema Bansal; Vishali Gupta
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379

8.  Clinical Characteristics of Paracentral Acute Middle Maculopathy in Eyes with Retinal Vascular Occlusion Diseases in Chinese Patients.

Authors:  Zhengwei Zhang; Yunjia Jiang; Xiaoli Huang; Zhifeng Wu; Bilian Ke
Journal:  J Ophthalmol       Date:  2021-06-18       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.